Moberg Pharma AB (publ) (MOB) fair value: what the stock is really worth
As of Oct 15, 2026: fair value of Moberg Pharma AB (publ) SEK 4.68, price SEK 11.34, upside -58.7%, quality 39 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand.
Show moreShow less
The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. It has license agreement with Karo Healthcare for distribution in European market. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.
Stock analysis
Moberg Pharma AB (publ) (MOB) currently trades at kr 11.34, while our model-based Fair Value estimate is kr 4.68, 58.7% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: kr 3.09 (bear) to kr 5.85 (bull), the price of kr 11.34 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Moberg Pharma AB (publ) reported revenue of 13.5M SEK in FY2025 versus 210M SEK in FY2021, a compound −49.6%/yr. Reported net income was −27.2M SEK in FY2025.
Key figures
Market cap 532M SEK (≈ $53.4M) · P/S ratio 31.0 · EPS (TTM) kr −0.4600 · Net margin −129% · Return on equity −3.2% · Return on assets (EBIT) −12.5% · Operating margin −82.0% · Revenue (TTM) 16.8M SEK.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 11 out of 100 (low confidence).
What moves the price
The share trades about 9% below its 52-week high and 46% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −24% fair-value upside, at −59%, MOB screens richer than that median.
Fair Value models
Bearkr 3.09Fair Value kr 4.68Bullkr 5.85
Price kr 11.34 · Upside -58.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+38.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−16.7%
Start year 2020 (pandemic). Over 10 years: −26.3% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.2%
’13
’14
’15
’16
’17
’18
’19
’20
’21
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−64.4% (2020) → −206.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Moberg Pharma AB (publ) with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 594 stocks
Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score39 · Bottom 25%
Fair Value upside−58.7% · Bottom 25%
Profitability
Return on assets−4.0% · Bottom 25%
Net margin (12 months)−129.0% · Bottom 25%
Operating margin (12 months)−82.0% · Bottom 25%
Growth and dividend
Revenue growth60.3% · Top 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/B0.08× · Cheapest 25%
P/S (12 months)3.19× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 19
FUTURE (revenue growth)100· sector 24
PAST (return on equity)0· sector 27
HEALTH (low debt)100· sector 96
DIVIDEND (yield)0· sector 31
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Moberg Pharma AB (publ) Fair Value". https://www.fairvalue-calculator.com/stock/MOB
Frequently asked questions
Is Moberg Pharma AB (publ) (MOB) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of kr 4.68 versus a price of kr 11.34, about −59% upside (overvalued).
What is the fair value of MOB?
Our model-based fair value for Moberg Pharma AB (publ) is kr 4.68 (as of Oct 2, 2026), built from audited fundamentals. The current price: kr 11.34.
What is the quality score of MOB?
Moberg Pharma AB (publ) has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Moberg Pharma AB (publ) (MOB)?
Our model-based price target is the fair value of kr 4.68 (as of Oct 2, 2026) from 1 valuation models. Cautious scenario kr 3.09, optimistic scenario kr 5.85. It is a calculation from audited fundamentals, not an analyst target.
What is the Moberg Pharma AB (publ) stock forecast for 2026?
Our models put fair value at kr 4.68, about −59% upside versus a price of kr 11.34 (overvalued). Cautious scenario kr 3.09, optimistic scenario kr 5.85. The calculation is refreshed regularly with new filings.
What is the revenue of Moberg Pharma AB (publ) (MOB)?
Moberg Pharma AB (publ) reported trailing-twelve-month revenue of about 16.8M SEK (latest available figure, as of Oct 2, 2026).
What is the intrinsic value of Moberg Pharma AB (publ) (MOB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Moberg Pharma AB (publ) it is kr 4.68 per share (as of Oct 2, 2026), against a price of kr 11.34. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Moberg Pharma AB (publ) stock overvalued or undervalued in 2026?
As of Oct 2, 2026, MOB trades above its calculated fair value: price kr 11.34, fair value kr 4.68, a gap of about −59% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MOB?
No. The price is what the market pays today (kr 11.34); the fair value is what the company's own numbers justify (kr 4.68). For Moberg Pharma AB (publ) the two are kr 6.66 per share apart. That gap is exactly why we show both numbers side by side.
How much is Moberg Pharma AB (publ) worth?
The market values Moberg Pharma AB (publ) at about 532M SEK (market capitalisation, as of Oct 2, 2026). Per share that is kr 11.34; our models calculate a fair value of kr 4.68 per share.
What do the bullish and bearish scenarios say about MOB?
Our models span a range for Moberg Pharma AB (publ): cautious scenario kr 3.09, base kr 4.68, optimistic kr 5.85 per share (as of Oct 2, 2026, price kr 11.34). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Moberg Pharma AB (publ) (MOB)?
Balance-sheet figures for Moberg Pharma AB (publ) (as of Oct 2, 2026): return on equity −3.2%. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is MOB from its 52-week high?
Moberg Pharma AB (publ) trades at kr 11.34, about 9% below its 52-week high of kr 12.40 and 46% above the low of kr 7.79 (as of Oct 15, 2026). Distance from the high says nothing about value: that is what the fair value of kr 4.68 is for.
Which stocks are comparable to Moberg Pharma AB (publ)?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Moberg Pharma AB (publ) stock attractive at the current price?
The data as of Oct 2, 2026: price kr 11.34, calculated fair value kr 4.68 (−59%), Quality Score 39/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MOB calculated?
We run Moberg Pharma AB (publ) through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 4.68, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.8 % above its aggregate fair value. Moberg Pharma AB (publ) itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Moberg Pharma AB (publ) (MOB)?
The closing price on Oct 15, 2026 was kr 11.34. Our model-based fair value is kr 4.68, about −59% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Moberg Pharma AB (publ) right now?
The price sits above even our optimistic bull case (kr 5.85). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (kr 3.09 to kr 5.85) leaves room in how you read the outcome.
Key figures of Moberg Pharma AB (publ)
How large is the market capitalisation of Moberg Pharma AB (publ) (MOB)?
The market capitalisation of Moberg Pharma AB (publ) is 532M SEK (≈ $53.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Moberg Pharma AB (publ) (MOB)?
The price-to-sales ratio of Moberg Pharma AB (publ) is 31.0 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Moberg Pharma AB (publ) (MOB)?
Earnings per share at Moberg Pharma AB (publ) are kr −0.4600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Moberg Pharma AB (publ) (MOB)?
The net margin of Moberg Pharma AB (publ) is −129% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Moberg Pharma AB (publ) (MOB)?
The return on equity (ROE) of Moberg Pharma AB (publ) is −3.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Moberg Pharma AB (publ) (MOB)?
On an EBIT basis the return on assets of Moberg Pharma AB (publ) is −12.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Moberg Pharma AB (publ) (MOB)?
The operating margin of Moberg Pharma AB (publ) is −82.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Moberg Pharma AB (publ) (MOB)?
Revenue at Moberg Pharma AB (publ) is growing +60.3% versus a year earlier (3y avg +303%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Moberg Pharma AB (publ) (MOB)?
Earnings per share at Moberg Pharma AB (publ) are growing −78.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Moberg Pharma AB (publ) (MOB) generate?
The free cash flow of Moberg Pharma AB (publ) is −60.7M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Moberg Pharma AB (publ) (MOB) hold?
Moberg Pharma AB (publ) holds more cash than debt, 228M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Moberg Pharma AB (publ) in the live analysis
One click puts Moberg Pharma AB (publ) on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
Thin data
Oct 2, 2026